Organon CMO exercises 11,519 RSUs, withholds shares

Organon & Co. executive Juan Camilo Arjona Ferreira, Head of R&D & CMO, reported an option-style event involving restricted stock units.

Rhea-AI Filing Summary

Organon & Co. executive Juan Camilo Arjona Ferreira, Head of R&D & CMO, reported an option-style event involving restricted stock units. On August 11, 2026 he exercised or converted 11,519 restricted stock units into the same number of common shares. In a related transaction, 4,134 common shares were delivered or withheld at $13.62 per share for payment of exercise price or tax liability. Footnotes state each restricted stock unit represents a contingent right to one common share and vesting occurs in three equal installments with the final vesting on August 11, 2026.

Insider Trade Summary

11,519 shares exercised/converted

Exercise 3 txns

Insider Arjona Ferreira Juan Camilo

Role Head of R&D & CMO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F1, F2	11,519	$0.00	$0.00
Exercise	Common Stock	11,519	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	4,134	$13.62	$56K

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 37,432.477 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.
2. F2. These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments with the third and final vesting occurring on August 11, 2026.

Key Figures

RSUs exercised or converted: 11,519 units Common shares acquired: 11,519 shares Shares delivered/withheld for costs: 4,134 shares +2 more

5 metrics

RSUs exercised or converted 11,519 units Restricted stock units converted into common stock on August 11, 2026

Common shares acquired 11,519 shares Shares of Organon common stock received from RSU exercise or conversion

Shares delivered/withheld for costs 4,134 shares Common shares delivered or withheld for payment of exercise price or tax liability

Per-share value for cost payment $13.62 per share Price applied to 4,134 shares for exercise price or tax liability

Final vesting date August 11, 2026 Third and final vesting of the restricted stock units

Key Terms

Restricted Stock Units, contingent right, vest, tax liability

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive one share of Organon & Co. common stock"

vest financial

"These restricted stock units vest and are distributed as shares of Organon common stock"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

tax liability financial

"Payment of exercise price or tax liability by delivering or withholding securities"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OGN executive Juan Camilo Arjona Ferreira report?

Juan Camilo Arjona Ferreira reported exercising or converting 11,519 restricted stock units into 11,519 shares of Organon common stock, plus a related disposition of 4,134 shares for payment of exercise price or tax liability.

How many Organon (OGN) shares were withheld or delivered for taxes or exercise costs?

A total of 4,134 common shares of Organon were delivered or withheld at $13.62 per share to cover payment of exercise price or tax liability associated with the restricted stock unit transaction.

What was the size of the RSU exercise reported for Organon (OGN)?

The filing shows an exercise or conversion of 11,519 restricted stock units, resulting in issuance of 11,519 shares of Organon common stock, with each restricted stock unit corresponding to one share of common stock.

Were the Organon (OGN) insider transactions under a Rule 10b5-1 plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, indicating these transactions were not reported as being made pursuant to a Rule 10b5-1 trading plan.

When do the reported Organon (OGN) restricted stock units fully vest?

Footnotes state the restricted stock units vest and are distributed in three equal installments, with the third and final vesting occurring on August 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 01:02 PM Accepted by SEC EDGAR 08/12/2026 - 01:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arjona Ferreira Juan Camilo

(Last) (First) (Middle)

C/O ORGANON &CO.

30 HUDSON STREET, FLOOR 33

(Street)

JERSEY CITY NEW JERSEY 07302

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of R&D & CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2026		M		11,519	A	$0	41,566.477	D
Common Stock	08/11/2026		F		4,134	D	$13.62	37,432.477	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	08/11/2026		M		11,519		(2)	(2)	Common Stock	11,519	$0	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

2. These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments with the third and final vesting occurring on August 11, 2026.

Remarks:

	/s/ Tarnetta Jones, as Attorney-in-fact for Dr. Juan Camilo Arjona Ferreira	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)